Flow Cytometry Pioneers Len and Lee Herzenberg to Join Invitrogen Flow Cytometry Scientific Advisory Board; Stanford Professor Leonard A. Herzenberg Ph.D. to Serve as Chairman.

CARLSBAD, Calif. -- Invitrogen Corp. (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced the formation of a Flow Cytometry Scientific Advisory Board to be chaired by Dr. Leonard A. Herzenberg. Dr. Leonore A. Herzenberg will join the board as a member. Together the two Stanford professors will help guide Invitrogen's efforts to bring its many product lines to bear on immunology, flow cytometry and cell biology.

More than 170,000 life science researchers worldwide now use the technique of flow cytometry, making it a cornerstone of immunology and other research areas such as cell signaling, viability and apoptosis. Additionally, it has been utilized for clinical diagnosis of leukemia/lymphoma and monitoring of HIV/AIDS disease and treatment progress. In the late 1960s, Len Herzenberg invented the Fluorescent Activated Cell Sorter which introduced now essential methods for isolating and studying individual living cells. He and Dr. Lee Herzenberg have continued to pioneer new developments in flow cytometry, and new ways of using this technology in basic and applied medical science, including recently, knowledge-based software systems, which make the design and analysis of state of the art flow cytometry experiments easy and widely accessible.

"Our connection to these pioneers of cell biology is vastly important as we expand our enabling technologies to new areas of medicine," explained John "Kip" Miller, Invitrogen's Senior Vice President, Enabling Technologies. "Their guidance will help us transform a number of our separate product areas into a system for immunology and continues our company's pursuit of solutions that span the continuum of scientific discovery. We are honored to have them help with our efforts."

Invitrogen has a broad range of technologies for cellular labeling, isolation and analysis including its Molecular Probes line of labels and dyes, Quantum Dot semiconductor nanocrystals, and Dynabeads from its Dynal business. Additionally, the company, through its acquisition of Caltag Laboratories, offers a collection of antibodies and reagents for immunology and the development of multi-color assays for flow cytometry. Flow cytometry is seen not only as a specific application for immunology, but also as a natural bridge between the company's efforts in molecular biology and cell biology.

"Invitrogen has a long history of developing technologies to advance research in the life sciences," said Len Herzenberg. "As the company's efforts move toward patient-directed disciplines such as immunology, we hope to help integrate several applicable areas to improve and expand the practice of flow cytometry in medicine."

As a part of the collaboration, the Herzenbergs will help establish an Invitrogen Scientific Advisory Board for immunology and flow cytometry, and design and endorse educational materials and courses to expand the usage of flow cytometry.

For more information on Invitrogen's immunodetection efforts, visit http://www.invitrogen.com/content.cfm?pageid=10610

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com.

Safe Harbor Statement / Forward-Looking Statements

Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to statements that: 1) The Herzenbergs will help guide Invitrogen's efforts in brining its product lines to bear on immunology, flow cytometry and cell biology; 2) The Herzenberg's guidance will transform disparate product groups into a system focused on specific applications; 3) Flow cytometry will be a bridge between the company's efforts in molecular and cell biology. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that: a) Invitrogen's focus areas are subject to change; b) Invitrogen may choose not to integrate product lines to apply to any specific application; and c) Invitrogen may keep its efforts in molecular and cell biology separate, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.